tetano
Editor, Senior Moderator
BMC Sports Sci Med Rehabil
. 2022 Apr 20;14(1):74.
doi: 10.1186/s13102-022-00464-8.
Cardiovascular complications and outcomes among athletes with COVID-19 disease: a systematic review
Bandar Alosaimi[SUP] 1 1 [/SUP], Isamme AlFayyad[SUP] 2 [/SUP], Salman Alshuaibi[SUP] 3 [/SUP], Ghazwaa Almutairi[SUP] 4 [/SUP], Nawaf Alshaebi[SUP] 5 [/SUP], Abdulaziz Alayyaf[SUP] 6 [/SUP], Wael Alturaiki[SUP] 7 [/SUP], Muhammad Azam Shah[SUP] 8 [/SUP]
Affiliations
Abstract
Background: Current evidence still emerging regarding the risk of cardiovascular (CV) sequel associated with coronavirus disease 2019 (COVID-19) infection, and considerable replicated studies are needed to ensure safe return-to-play. Therefore, we aimed in this systematic review to measure the prevalence of CV complications suffered by COVID-19 athletic patients, explore the outcomes, optimal approaches to diagnoses, and safe return-to-play considerations.
Methods: A systematic search on post COVID-19 infection quantitative studies among athletes was conducted following MeSH terms in Medline, Cochrane Library, Ovid, Embase and Scopus (through 15 January 2022). We included peer-reviewed studies reported athletes' CV complications and the outcomes post COVID-19 infection. Editorials, letters, commentaries, and clinical guidelines, as well as duplicate studies were excluded. Studies involving non-athletic patients were also excluded. Quality assessment was performed using Newcastle-Ottawa Scale.
Results: We included 15 eligible articles with a total of 6229 athletes, of whom 1023 were elite or professional athletes. The prevalence of myocarditis ranged between 0.4% and 15.4%, pericarditis 0.06% and 2.2%, and pericardial effusion between 0.27% and 58%. Five studies reported elevated troponin levels (0.9-6.9%).
Conclusions: This study provides a low prevalence of CV complications secondary to COVID-19 infection in short-term follow-up. Early recognition and continuous assessment of cardiac abnormality in competitive athletes are imperative to prevent cardiac complications. Establishing a stepwise evaluation approach is critical with an emphasis on imaging techniques for proper diagnosis and risk assessment for a safe return to play.
Keywords: Athletes; COVID-19; Cardiovascular; Extrapulmonary; Rehabilitation.
. 2022 Apr 20;14(1):74.
doi: 10.1186/s13102-022-00464-8.
Cardiovascular complications and outcomes among athletes with COVID-19 disease: a systematic review
Bandar Alosaimi[SUP] 1 1 [/SUP], Isamme AlFayyad[SUP] 2 [/SUP], Salman Alshuaibi[SUP] 3 [/SUP], Ghazwaa Almutairi[SUP] 4 [/SUP], Nawaf Alshaebi[SUP] 5 [/SUP], Abdulaziz Alayyaf[SUP] 6 [/SUP], Wael Alturaiki[SUP] 7 [/SUP], Muhammad Azam Shah[SUP] 8 [/SUP]
Affiliations
- PMID: 35443680
- DOI: 10.1186/s13102-022-00464-8
Abstract
Background: Current evidence still emerging regarding the risk of cardiovascular (CV) sequel associated with coronavirus disease 2019 (COVID-19) infection, and considerable replicated studies are needed to ensure safe return-to-play. Therefore, we aimed in this systematic review to measure the prevalence of CV complications suffered by COVID-19 athletic patients, explore the outcomes, optimal approaches to diagnoses, and safe return-to-play considerations.
Methods: A systematic search on post COVID-19 infection quantitative studies among athletes was conducted following MeSH terms in Medline, Cochrane Library, Ovid, Embase and Scopus (through 15 January 2022). We included peer-reviewed studies reported athletes' CV complications and the outcomes post COVID-19 infection. Editorials, letters, commentaries, and clinical guidelines, as well as duplicate studies were excluded. Studies involving non-athletic patients were also excluded. Quality assessment was performed using Newcastle-Ottawa Scale.
Results: We included 15 eligible articles with a total of 6229 athletes, of whom 1023 were elite or professional athletes. The prevalence of myocarditis ranged between 0.4% and 15.4%, pericarditis 0.06% and 2.2%, and pericardial effusion between 0.27% and 58%. Five studies reported elevated troponin levels (0.9-6.9%).
Conclusions: This study provides a low prevalence of CV complications secondary to COVID-19 infection in short-term follow-up. Early recognition and continuous assessment of cardiac abnormality in competitive athletes are imperative to prevent cardiac complications. Establishing a stepwise evaluation approach is critical with an emphasis on imaging techniques for proper diagnosis and risk assessment for a safe return to play.
Keywords: Athletes; COVID-19; Cardiovascular; Extrapulmonary; Rehabilitation.